Trellus Health plc (TRLS) Fair Value & Analysis
Healthcare · GB · Market cap 516K GBX
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from £0.1200 to £0.0013 (−98.9%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range £0.0012 – £0.0168 · the £0.0012 price screens below the £0.0013 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Trellus Health plc (TRLS) currently trades at £0.0012, while our model-based Fair Value estimate is £0.0013 — implying the stock looks roughly 8.8% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at £359K. It earns a return on equity of -56.7%. The balance sheet holds a net cash position of £4.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers GRITT resilience-based methodology; and TrellusElevate, a HIPAA-compliant technology platform for remote telemedicine care. Its platform provides support for managing inflammatory bowel disease, including Crohn's Disease and ulcerative colitis. The company was incorporated in 2020 and is headquartered in White Plains, New York.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Trellus Health plc reported revenue of £114K in FY2024 versus £25.0K in FY2021, a compound +65.8%/yr. Reported net income was −£7.8M in FY2024.
Is TRLS fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $86.03 | $54.47 | -37% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Trellus Health plc (TRLS) undervalued?
What is the fair value of TRLS?
What is the quality score of TRLS?
What is the revenue of Trellus Health plc (TRLS)?
What is the net profit margin of TRLS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.